Taken together, our results could not confirm the notion that MCAM expression represents a useful biomarker for disease progression but provide evidence that MCAM expression might represent part of a reactivated embryonal transcriptional program that facilitates melanoma–endothelial cell interactions during metastatic progression. This evidence concerns the gene MCAM and melanoma.